Medical artificial intelligence (AI) company Lunit (CEO Seo Beom-seok) announced on the 26th that it has supplied its AI cancer diagnosis solution to 11 Italian regional health offices (Azienda Sanitaria Locale, or ASL). These ASLs serve a population of approximately 8.5 million, representing approximately 14% of Italy's total population (approximately 58.9 million).
ASLs are the core institutions that operate Italy's public healthcare services at the regional level. Each ASL integrates and manages multiple medical institutions, including hospitals, health centers, and diagnostic centers, within its jurisdiction and provides healthcare services to local residents. Lunit's solutions have been implemented in five ASLs in the Lazio region, which includes the Rome metropolitan area; three in the Lombardy region, which includes the Milan metropolitan area; two in the Veneto region, which includes the greater Venice area; and one in the central Umbria region. These institutions encompass multiple medical institutions and are considered strategic hubs within the Italian healthcare system.
Through this agreement, Runit has expanded its business area to include the Mediterranean coastal region of Southern Europe, in addition to its existing Western, Northern, and Eastern European markets, establishing a business portfolio that encompasses all of Europe.
The supplied products are AI imaging diagnostic solutions, "Lunit Insight CXR" and "Lunit Insight MMG," which are currently integrated into ASL's imaging diagnostic system to support cancer diagnosis. This is particularly significant as Lunit's solutions are being practically applied within the Italian healthcare system, a country centered on public healthcare.
This supply is the result of Lunit's stable progress throughout the entire process from bidding to delivery through collaboration with local imaging diagnostic equipment distribution partners. Lunit plans to strengthen its position in the European B2G (business-to-government) medical market by combining partnerships with direct sales.
“Lunit is rapidly expanding its market share in the public healthcare sector in Europe and will continue to contribute to improving universal healthcare accessibility in more countries,” said Seo Beom-seok, CEO of Lunit. “We will solidify our position as a global healthcare AI company by expanding our business from Northern Europe to Southern Europe.”
Meanwhile, Runit is pursuing additional contracts with five ASLs in central and northern Italy by the end of this year. Once the contracts are completed, the population covered by its AI cancer diagnosis solution is expected to be approximately 12.3 million, or about 20% of the entire Italian population.
- See more related articles
You must be logged in to post a comment.